Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07649681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

Study acronym: GustaborRCT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Jul 1, 2026 to Jul 24, 2026
    • Site details revised at 6 of 6 sites
    v3
  2. Secondary endpoints revised (2)
    • Collaborators revised (5)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation. Although many non-pharmacological recommendations exist, it is unclear which methods are suitable for which individuals. This randomized study aims to compare the effectiveness of individualized dietary recommendations (Gustabor group) with the current standard of care -general recommendations (Control group). Participants will undergo an objective assessment of taste disorders using taste strips and questionnaires. Based on the results, the Gustabor group will receive both general and specific dietary suggestions. These will be accomapnied by AI-generated recipe suggestions tailored to specific taste disorders (e.g., more cold foods in cases of metallic taste). The control group will receive the current standard: a flyer containing general dietary advice for oncology patients previously shown to be beneficial for managing taste alterations. The primary endpoint is the PG-SGA score within 12 weeks of inclusion.
Trial Details
NCT Number NCT07649681
Lead Sponsor Wuerzburg University Hospital
Collaborators: LMU Klinikum, University Hospital Regensburg, University Hospital Erlangen, University Hospital Augsburg, TUM Klinikum
Conditions
(from sponsor)		 Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer), Urogenital Cancers
Related terms Gastrointestinal Neoplasms, Melanoma, Multiple Myeloma, Taste Disorders, Urogenital Neoplasms
Enrollment 198 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov